Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Purple Biotech Ltd.

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Purple Biotech Fortifies NT219 Patent Protection
From Purple Biotech Ltd.
Via GlobeNewswire
Tickers PPBT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.